

5 September 2022 Sydney, Australia

Presentation to E&P Small Caps Health Care Conference

Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation that will be given by Nyrada CEO, James Bonnar, at the E&P Small Caps Health Care Conference on 7 September 2022.

The presentation provides an overview of the Company's two lead drug development programs and an update on their progress as they advance towards Phase I first-in-human studies.

-ENDS-

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:
Laura Vize
Investor Relations Manager
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:
Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com



Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Improving Lives Through Innovation

Corporate Presentation

James Bonnar - CEO

September 2022

ASX: NYR

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc **(NYR** or **the Company**). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Portfolio of Novel High Value Small Molecule Drugs

	Indication	Aim	Target Market (US)	Status
Cardiovascular NYX-PCSK9i Oral PCSK9 inhibitor	Cholesterol lowering	Best-in-class small molecule drug to disrupt and broaden the class in CV management	**>18m** Patients[1]	Phase I Study: H1 CY2023
Neurology NYR-BI02 TRPC 3/6/7 blocker	Brain Injury	First-in-class treatment to prevent secondary brain injury following moderate-severe TBI, concussion, or stroke	**>3m** Patients / year[2]	Phase I Study: H1 CY2023

Commercially Focused Business Model

Focus Area	• **Novel small molecule treatments** for **serious and life-threatening diseases** where there is **unmet clinical need** and **large market share potential**
Development Objective	• Advance optimised drug candidates towards a **key value inflection point** of **confirming clinical safety and efficacy**
Growth Strategy	• **Build value** in lead drug assets by generating **clinical data** that **differentiates Nyrada's molecules as best-in-class**

Nyrada inc

Cholesterol-Lowering Drug Program

Novel small molecule PCSK9 Inhibitor



Cholesterol-Lowering Market

Population, Problem, Opportunity

62.6 million
Americans have high cholesterol[1]

56 million
between ages 40 and 75
treatment eligible

27.4 million
taking a statin[1]

18.4 million
Unable to achieve
LDL-C target despite taking a statin[1]

1 in 5 patients
statin intolerant[3]

Global Cholesterol Drugs Market

- USD 18.8 billion in 2021 (USD 14.7 billion statin drugs)[4]
- Est. sales revenue USD 30 billion by 2027 (**CAGR 8%**)[5]

Drivers of Market Growth

- Increasing rate of high cholesterol in patients
- Awareness of the benefits of cholesterol-lowering drugs
- New treatment options entering the market

Current PCSK9 Injectable Drugs

Expensive and Inconvenient

- ✓ Effective when combined with statin treatment
- ✗ Expensive US$5,800 to US$6,500 per year
- ✗ Inconvenient for patient / poor compliance
- ✗ Expensive to manufacture
- ✗ Insurer / patient co-pay reluctance (US)

Competitive advantages
of a small molecule PCSK9 inhibitor

- **Patient convenience**: once per day oral treatment
- **Lower manufacturing cost**
- Dose form **can be combined with a statin** (single pill)

Development of Drug Candidate NYX-PCSK9i

Discovery to Clinical Lead

Target Product Profile

- Small molecule suitable for once per day oral dosing
- Sufficiently potent in lowering LDL-C
- Safety / toxicology profile consistent with chronic dosing
- PCSK9 validated CVD target

Development Overview

- Novel accessible binding site was identified
- Screening of 1,100 FDA-approved drugs and nilotinib (TASIGNA®) emerged as a hit
- Over 400 analogs modeled, synthesised and tested for PCSK9 binding affinity
- NYX-PCSK9i emerged as lead candidate with nanomolar PCSK9 binding affinity, good oral bioavailability and drug-like properties



Evison *et al*. Bioorg. Med. Chem. (2020) **28**: 115344

Benchmarking Efficacy

NYX-PCSK9i +/- Lipitor® in Transgenic Mouse Hyperlipidemia Model

Study Objective:

Determine if additive reduction in total cholesterol can be achieved with combination statin therapy

- APOE*3Leiden.CETP mouse hyperlipidemia model
- Mouse treated for 35 days (50 mg/kg BID NYX-PCSK9i)

Results:

- **NYX-PCSK9i + Lipitor® achieves 65% total cholesterol reduction**
- **No effect on body weight, food intake, liver enzymes**

	% Difference in plasma cholesterol versus vehicle control (p-value)		
Time (days)	7	14	35
NYX-PCSK9i	-18% (0.066)	-24% **(0.002)**	-46% **(<0.001)**
Lipitor®	-13% (0.275)	-15% **(0.077)**	-27% **(<0.001)**
NYX-PCSK9i + Lipitor®	-33% **(<0.001)**	-49% **(<0.001)**	-65% **(<0.001)**

bold = statistically significant



Efficacy in Model of Atherosclerosis

NYX-PCSK9i in Human Tissue-Engineered Blood Vessel Model[6]

Study Design

- Researchers at Duke University (US) used human stem cells to create tissue-engineered blood vessels (TEBVs), replicating early features of atherosclerosis
- Evaluated the effect of PCSK9 inhibitor drug on inflammation and atherosclerotic plaque formation, a major cause of cardiovascular disease

Results:

- **Optimised analog of NYX-PCSK9i reduced cell adhesion (blocking atherosclerotic plaque formation)**
- **Nyrada's drug candidate reduced inflammatory response (cytokine levels) – a key driver of atherosclerosis**
- **Optimised analog of NYX-PCSK9i selected for Phase I**







Program Milestones and Path to the Clinic

2H CY2020

DEC 2020

NYX-PCSK9i shows 57% reduction in total cholesterol in mouse study

JULY 2020

NYX-PCSK9i demonstrates *ex vivo* equivalency to Repatha® and Praluent®

UNIVERSITÉ DE LA RÉUNION

1H CY2021

MAY 2021

Potent new drug candidates identified

JAN 2021

NYX-PCSK9i well tolerated, lowers LDL cholesterol in a dose-dependent manner

JUN 2021

NYX-PCSK9i reduces total cholesterol by 65% when given in combination with a statin, outperforms Lipitor® (atorvastatin, Pfizer)

2H CY2021

JUL 2021

USPTO grants patent for Nyrada's PCSK9i inhibitor technology

DEC 2021

Charles River Laboratories appointed to conduct preclinical studies in US

AUG 2021

NYX-PCSK9i mechanism of action confirmed following further exploratory analysis

UPCOMING

CY2022 - CY2023

Preclinical studies to commence in H2 CY2022
Phase I first-in-human clinical trial to commence H1 CY2023

JUNE 2022

EPO grants patent for Nyrada's PCSK9i inhibitor technology

Phase I Study Design

OBJECTIVES

- Evaluate safety, tolerability, and pharmacokinetics of NYX-PCSK9i
- Measure changes in LDL-cholesterol

DESIGN

- Double-blind, randomised, placebo-controlled, dose escalation study
- Single ascending oral dose (Cohorts 1-5)
- Once daily oral dose over 14-day treatment period (Cohorts 6, 7)
- Pharmacokinetic and pathology samples will be collected at selected time points over the trial period for all subjects.

PARTICIPANTS

- 56 healthy volunteers (18 to 50 years)
- 7 cohorts (6 active: 2 placebo per cohort)



Active arm

Placebo

LOCATION & DURATION

- Study will be conducted at a clinical trial centre in Australia
- The dosing period will vary between 1 – 14 days

*trial design subject to ethics approval

Brain Injury Drug Program

Novel small molecule TRPC 3/6/7 blocker

Brain Injury Market

Population, Problem, Opportunity

Each year

~5.5 million

People suffer a severe TBI[7]

55 million

People are living with the effects of medically treated TBI[7]

Each year

+12.2 million

suffer a stroke[8]

One drug class for stroke (tPA)
suitable for >15% of patients

TBI Treatment Market

- USD 6.7 billion sales revenue in 2020 (US, UK, Europe, Japan)[9]
- Sales revenue **CAGR 5%** to 2030[9]

Stroke Drug Market (tPA)

- USD 3.4 billion global revenue in 2018[10]
- Sales revenue **CAGR 7%** to 2027[10]

Problem and Opportunity

- **Unmet clinical need** with no approved drugs for TBI and limited treatment options for stroke
- **Effective treatment** will **improve patient outcomes** and **reduce high costs** associated with long-term care of brain injury survivors
- Moderate to severe TBI is an **orphan indication**

Nyrada is developing a first-in-class **neuroprotectant drug to prevent secondary injury**

Brain Injury Trajectory, Patient Outcomes, Treatment Aims



5-Year Patient Outcomes following TBI[11]



Data are US population estimates based on the TBIMS National Database. Data refer to people 16 years of age and older who received inpatient rehabilitation services for a primary diagnosis of TBI.

Nyrada drug NYR-BI02
An acute 3-day intravenous treatment

Reduce secondary injury resulting from TBI or stroke
- **Improve survivability, limit disability**
- **Improve quality of life**

TRPC 3/6/7 Ion Channels as a Therapeutic Target[12]

- **Glutamate release** following brain injury **results in calcium entry** via TRPC ion channels
- **Excessive calcium** build-up leads to **neuronal cell death**
- **Blocking TRPC 3/6/7 ion channels is neuroprotective** against secondary brain injury



Proof of Concept
Knockout Model shows Neuroprotection

TTC Staining



Functional Improvement following Brain Injury in TRPC 3/6/7 KO Mice[13]



Adapted from Chen et al. Mol. Neurobiol. 2017

- TRPC 3/6/7 KO mice have significantly **smaller lesion sizes** compared to WT
- TRPC 3/6/7 KO mice have significantly **better neurological score** compared to WT
- Nyrada molecule **NYR-BI02 blocks TRPC3/6/7 channels** (IC_{50} = 0.6 µM)
- **NYR-BI02 will be tested in models of TBI (WRAIR) and stroke CY2023**

Program Milestones and Path to the Clinic

2H CY2020

JUL 2020

- Nyrada Brain Injury Data published at the premier US Military Health conference, US Military Health System Research Symposium
- Drug candidates successfully delivered by continuous intravenous infusion, maintaining effective therapeutic levels in the brain, with no adverse effects observed
- Pilot study evaluating the intranasal route of delivery for drug candidates

CY2021

FEB 2021

- Collaboration secured with WRAIR and UNSW Sydney

JUN 2021

- New, more potent analog of Nyrada's brain injury candidate identified (NYR-BI01)
- Pilot work to optimise PTBI model, drug formulation and delivery, and MRI scanning, (WRAIR & UNSW Sydney)

WRAIR Walter Reed Army Institute of Research Soldier Health • World Health

UNSW SYDNEY

CY2022 – CY2023

MAR 2022

- NYR-BI02 selected for Phase I study

MAY 2022

- Provisional patent application filed

UPCOMING

- Brain injury drug candidate testing in preclinical model of stroke in Q4 CY2022
- Complete PTBI efficacy study
- Phase I first-in-human study anticipated to commence first half of CY2023
- Study will support Phase II development in Moderate-severe TBI and stroke (acute IV dosing)

Phase I Study Design

OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI02

DESIGN

- Randomised, double-blind placebo – controlled, dose escalation design
- 5 cohorts; 8 participants each cohort; 6:2 active and placebo treatments
- 3 cohorts will be single ascending doses
- 2 cohorts will be given continuous infusion doses

PARTICIPANTS

- Male and female healthy volunteers
- 18 – 50 years age

Cohort number	Dose administered
1	Low dose single bolus
2	Medium dose single bolus
3	High dose
4	Low dose continuous infusion (72 hrs)
5	High dose continuous infusion (72 hrs)

LOCATION & DURATION

- Study will be conducted at a clinical trial centre in Australia
- The study duration will vary between 1 – 4 days



*trial design subject to ethics approval

Corporate Snapshot

ASX:NYR

Corporate Snapshot

Key Metrics	
Market capitalisation (as at 2 September 2022)	**A$24.2M**
Share price (as at 02 September 2022)	**A$0.155**
CDIs free float	**156,008,700**
Cash at bank 30 June 2022: • Adequate funding for Phase I studies	**A$10.8M**
ASX listing	**January 16, 2020**

Management Team with Proven Industry Experience

James Bonnar - CEO

- Business executive with 25 years experience in healthcare companies in the UK, China, New Zealand, and Australia
- Experience in drug manufacture, preclinical development, clinical operations, regulatory affairs, and quality assurance
- Biotech experience spanning various therapeutic areas including cardiometabolic disease, neurodevelopment disorders, and brain injury

Cameron Jones - CFO

- Finance executive with experience as CFO and Company Secretary of ASX Listed and VC investee healthcare companies
- Supported several healthcare companies through IPOs, capital raisings and M&A transactions
- Managing Director of Bio101, financial services firm
- Chartered Accountant, Member of the Governance Institute of Australia and Registered Tax Agent

Dr Benny Evison - CSO

- More than 20 years experience in the discovery and development of small molecule inhibitors as therapies for various cancers, cardiovascular diseases and neurodegenerative diseases
- Obtained a PhD at La Trobe University (Melbourne, Australia) in biochemistry and molecular biology, and a postdoctoral fellowship in chemical biology at St Jude Children's Research Hospital, (Memphis TN)

High calibre Board with proven track record in realising the value of biotech companies:

- **John Moore**
  Chairman
- **Christopher Cox**
  Non-Executive Director
- **Marcus Frampton**
  Non-Executive Director
- **Dr Rüdiger Weseloh**
  Non-Executive Director
- **Dr Ian Dixon**
  Non-Executive Director
- **Dr Gisela Mautner**
  Non-Executive Director

Summary

Best-in-class small molecule PCSK9 inhibitor

- Oral, once per day dosing, patient convenience
- Manufacturing and cost advantages over biologics and peptides
- Can be administered with a statin to achieve additive therapeutic effect (monotherapy or combination)

First-in-class treatment to prevent secondary brain injury

- TBI and stroke
- Novel biological target – TRPC 3/6/7 ion channels
- Collaboration with WRAIR and UNSW - opportunity to pursue non-dilutive funding

Strong cash position

- A$10.8M as at 30 June 2022
- Adequate funding for Phase I studies

References

1 Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016

2 Brain Injury Alliance (Connecticut): http://www.biact.org/understanding-brain-injury/brain-injury-facts-statistics and US Centers for Disease Control and Prevention: https://www.cdc.gov/stroke/facts.htm

3 Management of Statin Intolerance in 2018: Still More Questions Than Answers, Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Am J Cardiovasc Drugs. 2018 Jun;18(3):157-173

4 Cholesterol Lowering Drug Market Research Report by Disease Type, Class of Drug, Distribution Channels, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19, July 2022 and Global Statin Market – Industry Trends and Forecast to 2029, Data Bridge Market Research

5 Cholesterol Lowering Drug Market Research Report by Disease Type, Class of Drug, Distribution Channels, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19, July 2022

6 Adapted from Zhang et al. Nat Commun. 2020. 11(1): 5426 and modified from Nature cell biology, 17(8), 994-1003

7 National Academies of Sciences, Engineering, and Medicine 2022. Traumatic Brain Injury: A Roadmap for Accelerating Progress. Washington, DC: The National Academies Press. https://doi.org/10.17226/25394

8 World Stroke Organisation (WSO): Global Stroke Factsheet 2022,Valery L Feigin et al, International Journal of Stroke 2022, Vol. 17(1) 18–29

9 Global Traumatic Brain Injury Market to 2030 - Insight, Epidemiology and Forecast by ResearchAndMarkets.com

10 Stroke Treatment Market Insight and Trends 2027 - TMR (transparencymarketresearch.com)

11 'Moderate to Severe Traumatic is a Lifelong Condition', CDC publication available at: https://www.cdc.gov/traumaticbraininjury/pdf/moderate_to_severe_tbi_lifelong-a.pdf

12 Jeon J, Bu F, Sun G, Tian J,Ting S, Li J,Aronowski J, Birnbaumer L, Freichel M, and Zhu MX (2020). Contribution of TRPC Channels in Neuronal Excitotoxicity Associated With Neurodegenerative Disease and Ischemic Stroke. Front Cell Dev Biol. doi: 10.3389/fcell.2020.618663

13 Chen X, Lu M, He X, Ma L, Birnbaumer L, and Liao, Y. (2017). TRPC3/6/7 knockdown protects the brain from cerebral ischemia injury via astrocyte apoptosis inhibition and effects on NF-small ka, CyrillicB translocation. Mol. Neurobiol. 54, 7555–7566. doi: 10.1007/s12035-016-0227-2

Nyrada inc

Brain Injury Solution Animation	Cholesterol-Lowering Animation